dPCR MRD Assay

About Tracer Biotechnologies

Tracer Biotechnologies is pioneering a decentralized, vendor-agnostic platform to democratize access to ultrasensitive Minimal Residual Disease (MRD) monitoring in oncology. Their core innovation is a software layer that, combined with advanced AI, enables existing NGS and dPCR instruments to achieve single-part-per-million (ppm) sensitivity using generic, low-cost reagents, eliminating vendor lock-in. By decentralizing the testing workflow, Tracer addresses critical bottlenecks in cancer care logistics—such as tissue limitations, lengthy turnaround times, and centralized lab dependencies—empowering hospitals, CROs, and biopharma sites to conduct MRD testing locally. The company has announced a strategic partnership with AstraZeneca, signaling early validation of its platform for global clinical research.

Therapeutic Areas

Other Minimal Residual Disease (Cancer) Drugs